CELLSEEKER
Dead / Abandoned — Abandoned — failure to respond (as of 16 Oct 2025)
What this means for you
This application is over — abandoned 06 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98795718
- Mark type
- Stylized text
- Filed
- 10 Oct 2024
- Abandoned
- 06 Oct 2025
- Attorney of record
- Joi A. White
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; systems to express therapeutic proteins in vivo; gene therapy products; gene therapy preparations; in vivo nucleic acid, DNA, RNA, and mRNA technologies; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; cell engineering platforms; cell engineering platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy; technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; technology platforms for delivery of a nucleic acid payload; technology platforms for delivery of a negatively charged payload; biologics delivery systems; biologics delivery platforms; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles;
Owner
- CAPSTAN THERAPEUTICS, INC., San Diego, CA, US
Prosecution history
- 16 Oct 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 16 Oct 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 30 Jun 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 30 Jun 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 03 Apr 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 03 Apr 2025 — NON-FINAL ACTION E-MAILED
- 03 Apr 2025 — NON-FINAL ACTION WRITTEN
- 21 Mar 2025 — ASSIGNED TO EXAMINER
- 11 Oct 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 11 Oct 2024 — NEW APPLICATION ENTERED